| |
|
|
|
|
|
|
|||
|
Blood, 1 October 2004, Vol. 104, No. 7, pp. 1989-1994. Prepublished online as a Blood First Edition Paper on June 17, 2004; DOI 10.1182/blood-2004-02-0628.
Submitted February 19, 2004
Medizinische Klinik-Innenstadt, Munich, Germany * Corresponding author; email: christian.straka{at}med.uni-muenchen.de.
An active assessment of the host capacity to prevent infection during myelosuppression should be beneficial in patients receiving high-dose chemotherapy. A single dose of G-CSF (5 µg/kg) was given to 57 patients with multiple myeloma early after the completion of 85 high-dose chemotherapy (melphalan 200 mg/m2) courses. This provoked a highly variable white blood cell (WBC) peak after 12-14 hours. The median WBC count was 21000/µL (range 6400-60600/µL) after a first high-dose therapy (n=50) and 13500/µL (range 4700-24800/µL) after a second high-dose therapy (n=35). The responsiveness to single G-CSF was associated with the risk of infection during subsequent cytopenia (p=0.003). This association was significant after adjustment for neutropenia duration. Notably, the result of testing G-CSF responsiveness is timely available before the onset of leukopenia and G-CSF responsiveness was more informative than neutropenia duration regarding the risk of infection. Furthermore, there was an association between the responsiveness to G-CSF and stem cell engraftment (p <0.005), which remained significant after adjustment for the number of transplanted CD34+ cells. Our results show for the first time that G-CSF potentially could be used for an early in vivo assessment of defense to infection in recipients of high-dose chemotherapy.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2004 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||